190 related articles for article (PubMed ID: 38173731)
41. T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J; Shen K; Mu W; Li W; Zhang M; Zhang W; Li Z; Ge T; Zhu Z; Zhang S; Chen C; Xing S; Zhu L; Chen L; Wang N; Huang L; Li D; Xiao M; Zhou J
Front Immunol; 2022; 13():873789. PubMed ID: 35572515
[TBL] [Abstract][Full Text] [Related]
42. Case report: Hashimoto's thyroiditis after CD19 chimeric antigen receptor T-cell therapy.
Chen P; Xia Y; Lei W; Zhong S; Jiang H; Ren L; Qian W; Liu H
Front Immunol; 2022; 13():995496. PubMed ID: 36389794
[TBL] [Abstract][Full Text] [Related]
43. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
[TBL] [Abstract][Full Text] [Related]
45. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
[TBL] [Abstract][Full Text] [Related]
46. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
47. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.
Ram R; Grisariu S; Shargian-Alon L; Amit O; Bar-On Y; Stepensky P; Yeshurun M; Avni B; Hagin D; Perry C; Gurion R; Sarid N; Herishanu Y; Gold R; Glait-Santar C; Kay S; Avivi I
Haematologica; 2022 May; 107(5):1111-1118. PubMed ID: 34233446
[TBL] [Abstract][Full Text] [Related]
48. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Roddie C; Lekakis LJ; Marzolini MAV; Ramakrishnan A; Zhang Y; Hu Y; Peddareddigari VGR; Khokhar N; Chen R; Basilico S; Raymond M; Vargas FA; Duffy K; Brugger W; O'Reilly MA; Wood L; Linch DC; Peggs KS; Bachier C; Budde EL; Lee Batlevi C; Bartlett N; Irvine D; Tholouli E; Osborne W; Ardeshna KM; Pule MA
Blood; 2023 May; 141(20):2470-2482. PubMed ID: 36821767
[TBL] [Abstract][Full Text] [Related]
49. Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.
Zhu W; Tao S; Miao W; Liu H; Yuan X
Front Immunol; 2022; 13():894787. PubMed ID: 35757723
[TBL] [Abstract][Full Text] [Related]
50. A safe and potent anti-CD19 CAR T cell therapy.
Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
[TBL] [Abstract][Full Text] [Related]
51. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study.
Wang J; Alkrekshi A; Dasari S; Lin HC; Elantably D; Armashi ARA
Bone Marrow Transplant; 2023 Nov; 58(11):1223-1228. PubMed ID: 37604871
[TBL] [Abstract][Full Text] [Related]
52. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.
Yang J; He J; Zhang X; Li J; Wang Z; Zhang Y; Qiu L; Wu Q; Sun Z; Ye X; Yin W; Cao W; Shen L; Sersch M; Lu P
Blood Cancer J; 2022 Jul; 12(7):104. PubMed ID: 35798714
[TBL] [Abstract][Full Text] [Related]
53. Breast lymphoma in Sjögren's syndrome complicated by acute monocular blindness.
Soldevilla HF; Molina RM; Navarra SV
Int J Rheum Dis; 2010 May; 13(2):164-70. PubMed ID: 20536602
[TBL] [Abstract][Full Text] [Related]
54. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
55. A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.
Zhao H; Wang Y; Yin ETS; Zhao K; Hu Y; Huang H
Front Med; 2020 Dec; 14(6):711-725. PubMed ID: 33259039
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
57. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
[No Abstract] [Full Text] [Related]
58. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
59. EBV-positive diffuse large B-cell lymphoma in a patient with primary Sjögren's syndrome and membranous glomerulonephritis.
Kim CS; Choi YD; Choi JS; Bae EH; Ma SK; Kim SW
BMC Nephrol; 2012 Nov; 13():149. PubMed ID: 23151312
[TBL] [Abstract][Full Text] [Related]
60. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS; Locke FL; Bartlett NL; Lekakis LJ; Miklos DB; Jacobson CA; Braunschweig I; Oluwole OO; Siddiqi T; Lin Y; Timmerman JM; Stiff PJ; Friedberg JW; Flinn IW; Goy A; Hill BT; Smith MR; Deol A; Farooq U; McSweeney P; Munoz J; Avivi I; Castro JE; Westin JR; Chavez JC; Ghobadi A; Komanduri KV; Levy R; Jacobsen ED; Witzig TE; Reagan P; Bot A; Rossi J; Navale L; Jiang Y; Aycock J; Elias M; Chang D; Wiezorek J; Go WY
N Engl J Med; 2017 Dec; 377(26):2531-2544. PubMed ID: 29226797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
